Effective Circulating Tumor Cell Isolation Using Epithelial and Mesenchymal Markers in Prostate and Pancreatic Cancer Patients

Circulating tumor cells (CTCs) display antigenic heterogeneity between epithelial and mesenchymal phenotypes. However, most current CTC isolation methods rely on EpCAM (epithelial cell adhesion molecule) antibodies. This study introduces a more efficient CTC isolation technique utilizing both EpCAM...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2023-05, Vol.15 (10), p.2825
Main Authors: Cha, Jiwon, Cho, Hyungseok, Chung, Jae-Seung, Park, Joon Seong, Han, Ki-Ho
Format: Article
Language:English
Subjects:
Antibodies
Blood & organ donations
Care and treatment
Cell adhesion molecules
Comparative analysis
Diagnosis
Efficiency
Epithelial cells
Ethylenediaminetetraacetic acid
Magnetic fields
Metastases
Metastasis
Nanoparticles
Pancreatic cancer
Patient compliance
Patients
Phenotypes
Polyethylene terephthalate
Prognosis
Prostate
Prostate cancer
Stem cells
Tumor cells
Tumors
Vimentin
Viral antibodies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Circulating tumor cells (CTCs) display antigenic heterogeneity between epithelial and mesenchymal phenotypes. However, most current CTC isolation methods rely on EpCAM (epithelial cell adhesion molecule) antibodies. This study introduces a more efficient CTC isolation technique utilizing both EpCAM and vimentin (mesenchymal cell marker) antibodies, alongside a lateral magnetophoretic microseparator. The effectiveness of this approach was assessed by isolating CTCs from prostate ( = 17) and pancreatic ( = 5) cancer patients using EpCAM alone, vimentin alone, and both antibodies together. Prostate cancer patients showed an average of 13.29, 11.13, and 27.95 CTCs/mL isolated using EpCAM alone, vimentin alone, and both antibodies, respectively. For pancreatic cancer patients, the averages were 1.50, 3.44, and 10.82 CTCs/mL with EpCAM alone, vimentin alone, and both antibodies, respectively. Combining antibodies more than doubled CTC isolation compared to single antibodies. Interestingly, EpCAM antibodies were more effective for localized prostate cancer, while vimentin antibodies excelled in metastatic prostate cancer isolation. Moreover, vimentin antibodies outperformed EpCAM antibodies for all pancreatic cancer patients. These results highlight that using both epithelial and mesenchymal antibodies with the lateral magnetophoretic microseparator significantly enhances CTC isolation efficiency, and that antibody choice may vary depending on cancer type and stage.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers15102825